LT2008003A - Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas - Google Patents

Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas

Info

Publication number
LT2008003A
LT2008003A LT2008003A LT2008003A LT2008003A LT 2008003 A LT2008003 A LT 2008003A LT 2008003 A LT2008003 A LT 2008003A LT 2008003 A LT2008003 A LT 2008003A LT 2008003 A LT2008003 A LT 2008003A
Authority
LT
Lithuania
Prior art keywords
meldonium
reverse transcriptase
transcriptase inhibitor
basis
pharmaceutical composition
Prior art date
Application number
LT2008003A
Other languages
English (en)
Other versions
LT5524B (lt
Inventor
Vija Klusha
Sergejs Isajevs
Jolanta Pupure
Juris Rumaks
Valentina Gordjushina
Immanuels Taivans
Ivars Kalvinsh
Original Assignee
Latvian Institute Of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2008003(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Latvian Institute Of Organic Synthesis filed Critical Latvian Institute Of Organic Synthesis
Publication of LT2008003A publication Critical patent/LT2008003A/lt
Publication of LT5524B publication Critical patent/LT5524B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Naujos farmacinės kompozicijos, kurios turi vienąarba kelis atvirkštinės transkriptazės inhibitorius, t.y. zidovudino, lamivudino arba stavudino kliniškai veiksmingą kiekį, ir meldoniumo, o taip patfarmaciškai priimtinų nešiklių. Buvo įrodyta, kadmeldoniumo įtraukimas į šias farmacines kompozicijas iš esmės sumažina atvirkštinės transkriptazės inhibitoriaus kardio ir neurotoksiškumą.
LT2008003A 2005-08-15 2008-01-18 Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas LT5524B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium

Publications (2)

Publication Number Publication Date
LT2008003A true LT2008003A (lt) 2008-07-25
LT5524B LT5524B (lt) 2008-10-27

Family

ID=37442067

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2008003A LT5524B (lt) 2005-08-15 2008-01-18 Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas

Country Status (17)

Country Link
US (1) US7700576B2 (lt)
EP (1) EP1933823B1 (lt)
JP (1) JP5027809B2 (lt)
CN (1) CN101252925B (lt)
AR (1) AR066995A1 (lt)
AT (1) ATE493123T1 (lt)
DE (1) DE602006019293D1 (lt)
EE (1) EE05529B1 (lt)
ES (1) ES2361185T3 (lt)
HN (1) HN2006029085A (lt)
LT (1) LT5524B (lt)
LV (1) LV13544B (lt)
PE (1) PE20070233A1 (lt)
SV (1) SV2007002655A (lt)
UA (1) UA90162C2 (lt)
UY (1) UY29751A1 (lt)
WO (1) WO2007021164A1 (lt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1009600A2 (lt) * 2009-06-25 2016-03-22 Tetra S A
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompoz&imacr;cija trimetilam&imacr;na-N-oks&imacr;da l&imacr;me&ncedil;a pazemin&amacr;&scaron;anai

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997646A1 (ru) 1978-11-27 1983-02-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Кормова добавка
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1255039B (it) 1992-03-11 1995-10-13 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.

Also Published As

Publication number Publication date
PE20070233A1 (es) 2007-06-08
SV2007002655A (es) 2007-04-12
ES2361185T3 (es) 2011-06-14
JP5027809B2 (ja) 2012-09-19
AR066995A1 (es) 2009-09-30
HN2006029085A (es) 2007-11-16
UY29751A1 (es) 2007-03-30
EP1933823B1 (en) 2010-12-29
CN101252925B (zh) 2012-04-25
LT5524B (lt) 2008-10-27
EE200800014A (et) 2008-06-16
DE602006019293D1 (de) 2011-02-10
US7700576B2 (en) 2010-04-20
UA90162C2 (ru) 2010-04-12
JP2009504731A (ja) 2009-02-05
WO2007021164A1 (en) 2007-02-22
US20090137522A1 (en) 2009-05-28
LV13544B (en) 2007-05-20
CN101252925A (zh) 2008-08-27
EP1933823A1 (en) 2008-06-25
EE05529B1 (et) 2012-04-16
ATE493123T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
TW200738817A (en) Blends of biopolymers with acrylic copolymers
EA200701793A1 (ru) Состоящие из наночастиц композиции доцетаксела и его аналогов
WO2007002204A3 (en) Pyrosequencing methods and related compostions
IL192631A (en) A drug containing an isolated antibody or a functional portion thereof, pharmaceutical preparations and a kit containing it
EP2586778A3 (en) Pyridazinone derivatives useful as glucan synthase inhibitors
CR10680A (es) Composiciones de inhibidores de chk1
WO2008042231A3 (en) Compositions and methods for evaluating and treating heart failure
TW200740799A (en) Alpha2C adrenoreceptor agonists
UY31209A1 (es) Uso de homo y copolimeros para la estabilización de formulaciones de principios activos
NO20080785L (no) Behandling av kreft
WO2008024473A3 (en) Mapping of genomic interactions
MA28999B1 (fr) Compositions destinees a lutter contre un ou plusieurs pathogenes
WO2007106436A3 (en) Photoactive compounds and compositions and uses thereof
WO2004091645A3 (en) Composition comprising rosmarinic acid, borneol and ginsenoside
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
WO2007017196A3 (de) Öl-in-wasser emulsionen
WO2008013550A8 (en) Substituted phenylsulfur trifluoride and other like fluorinating agents
EA200701029A1 (ru) Новая композиция для облегчения человеческих родов
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007067519A3 (en) The use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
WO2005108416A3 (en) Myosin light chain kinase inhibitors and their use
MX2007001953A (es) Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20140808